Chemotherapy in Hormone Refractory Prostate Cancer: Where Do We Stand?
- 31 December 2004
- journal article
- editorial
- Published by Elsevier in European Urology
- Vol. 46 (6) , 709-711
- https://doi.org/10.1016/j.eururo.2004.08.023
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Weekly Docetaxel and Vinorelbine (VIN-DOX) as First Line Treatment in Patients with Hormone Refractory Prostate CancerEuropean Urology, 2004
- Efficacy and safety of trastuzumab.Expert Opinion on Drug Safety, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- The management of hormone‐relapsed prostate cancerBJU International, 2003
- Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled TrialJournal of Clinical Oncology, 2003
- A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate CarcinomaJNCI Journal of the National Cancer Institute, 2002
- Treatment with radioactive 89strontium for patients with bone metastases from prostate cancerBJU International, 2000
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996